The patent describes the technical solution that allows SpectraCure's treatment system to use the same optical fibers (light guide) to deliver the treatment light and to perform the measurements, to enable individual treatment. The solution of using the same optical fibers for measurement as for treatment, makes SpectraCure unique.
"SpectraCure's original basic patent, created by Professor Sune Svanberg, describes this solution. In the basic patent, which is used in the first generation treatment system, movable optomechanical switches are used to achieve the function. In the new generation system, a completely different technical solution based on fixed components is used”, explains Johannes Swartling, CTO.
In addition to this new patent, SpectraCure has extensive patent protection for IDOSE®, the algorithms that regulate the treatment.
"This new patented technology makes the system smaller, simpler and cheaper to manufacture and maintain. In addition, it also provides a potentially better clinical performance. This new patent means that we are renewing the patent protection for SpectraCure's basic technology, which is very important for the company", says SpectraCure's CEO Johan Folkunger.
Outside of Europe, the same patent application is in PCT phase, i.e. international examination. SpectraCure intends to seek patent protection in the most important markets outside of Europe.
For further information:
SpectraCure AB (publ) Johan Folkunger, CEO
SpectraCure is developing a treatment system for the elimination of internal solid cancer tumors. We are initially focusing on recurrent prostate cancer, with the hope of being able to treat other cancers such as primary prostate cancer, breast cancer, pancreatic cancer, and head and neck cancer in the future. The approach is based on a proprietary and patented treatment system consisting of a hardware device, a laser unit, which performs PDT treatment and treats the prostate itself, combined with a software device, the patented IDOSE® dose planning platform. The method allows the laser light dose to be controlled so that the tumour is exposed to an optimal dose to achieve sufficient treatment effect. The treatment system has the potential to make interstitial PDT treatment accurate, precise, safe for every patient. The goal is that in addition to being tumor free, the patient will be able to maintain their quality of life, with limited side effects. We are conducting clinical trials as an important part of the continued development of the company's treatment system.
The company is listed in the Premier segment of the Nasdaq First North Growth Market with G&W Fondkommission as Certified Adviser, email@example.com, tel +468-503 00 050, and trades under the short name SPEC.